All In Biotech

Drug Trial Radar · NCT04432454

Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

An Open-label, Multicenter Study Evaluating the Safety of Lasofoxifene in Combination With Abemaciclib for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer and Have an ESR1 Mutation ( ELAINEII )

Last checked: Nov 19, 2026Latest source record: Feb 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

29

Actual

Start

Sep 29, 2020

Primary completion

Jan 28, 2025

Study completion Jan 28, 2025

Sponsor

Lead sponsor
Sermonix Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Jun 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter, single-arm safety study evaluating the safety and tolerability of the lasofoxifene and abemaciclib combination for the treatment of pre- and postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on first and/or 2nd lines of hormonal treatment for metastatic disease and have an ESR1 mutation.

Conditions

  • Metastatic Breast Cancer

Interventions

  • Lasofoxifene and abemaciclib (VERZENIO (R)).Drug

    Lasofoxifene 5 mg given once a day orally and abemaciclib 150 mg given twice a day orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of the combination of lasofoxifene and abemaciclib as measured by number of adverse events (AEs), severity of AEs and mortality due to AEs at every scheduled visit.Time frame: All subjects enrolled in the study will be treated until documented disease progression or until withdrawal for any reason. Safety and tolerability will be assessed from enrollment up to 24 months.

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham (UAB) - Comprehensive Cancer Center

    Birmingham, Alabama

  • Yuma Regional Medical Center

    Yuma, Arizona

  • Compassionate Cancer Care Med Group - Clinic Aid USA - Fountain Valley

    Fountain Valley, California

  • St. Joseph Health

    Santa Rosa, California

  • Mayo Jacksonville

    Jacksonville, Florida

  • Illinois Cancer Care

    Peoria, Illinois

  • Beacon Health System Memorial Regional Cancer Center

    South Bend, Indiana

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • New Jersey Cancer Care, PA

    Belleville, New Jersey

  • Cleveland Clinic

    Cleveland, Ohio

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • Mary Crowley Cancer Research

    Dallas, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Oncology Consultants, P.A.

    Houston, Texas

  • Hematology Oncology Associates of Fredericksburg

    Fredericksburg, Virginia

  • Northwest Medical Specialists, PLLC (NWMS)

    Tacoma, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.